Bitcoin Futures Go Live at the CME, and Congress Calls for a Disney Hearing
A week after contracts on the cryptocurrency began trading at the CBOE, the much larger derivatives exchange, the CME, launches its own version. Interest in Bitcoin and other digital assets has risen exponentially this year, with prices approaching $20,000 over the weekend.
Plus days after Disney announced its $52 billion acquisition of Fox, Democratic leaders in Congress are calling for a hearing, raising antitrust concerns. The legislators saying a deal would concentrate too much box office power in one company.
And a judge made public a letter from a former Uber employee which accuses former executives of espionage and bribery. Stitch Fix is getting ready for its first earnings report since going public. We've also got earnings on tap from BlackBerry and Micron.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
